-+ 0.00%
-+ 0.00%
-+ 0.00%

BGM Group (BGM) Stock Faces EPS Swing To Loss Challenges Bullish Growth Narratives

Simply Wall St·07/22/2026 03:26:36
语音播报

BGM Group (BGM) has reported FY 2025 first half revenue of about US$14.3 million and a basic EPS loss of US$0.03 per share, setting a mixed tone for investors watching the company’s momentum against a higher revenue base. The company has seen revenue move from roughly US$12.6 million in the first half of FY 2024 to US$14.3 million in the first half of FY 2025, while basic EPS shifted from a profit of US$0.06 to a loss of US$0.03. This puts the spotlight firmly on how much of that top line is translating into sustainable margins.

See our full analysis for BGM Group.

With the headline numbers on the table, the next step is to set BGM Group’s recent results against the prevailing market narratives to see where the story around growth, risks, and profitability still holds up and where it starts to crack.

Curious how numbers become stories that shape markets? Explore Community Narratives

NasdaqCM:BGM Revenue & Expenses Breakdown as at Jul 2026
NasdaqCM:BGM Revenue & Expenses Breakdown as at Jul 2026

51.1% revenue growth alongside continuing losses

  • Over the last 12 months, BGM Group reported revenue of US$37.9 million and a 51.1% rise in revenue against a trailing net loss of US$19.9 million.
  • What stands out for bullish investors is that strong top line growth sits next to a trailing loss, which means any optimistic view has to reconcile higher revenue with basic EPS moving from a profit of US$0.06 in the first half of FY 2024 to a loss of roughly US$0.03 in the first half of FY 2025.
    • Supporters of the bullish case may point to the shift from US$12.6 million to US$14.3 million in first half revenue as proof that customers are still spending with BGM Group.
    • At the same time, the move from first half net income of US$0.4 million in FY 2024 to a first half loss of US$0.9 million in FY 2025 shows that costs are currently running ahead of that extra revenue.

Investors who want to see how these mixed signals fit into the wider story around BGM Group’s valuation and risk profile can tap into a broader community view through 📊 Read the what the Community is saying about BGM Group..

Trailing 12 month loss of US$19.9 million

  • Across the trailing 12 months, BGM Group recorded a net loss of US$19.9 million and a basic EPS loss of about US$0.18 alongside US$37.9 million in revenue.
  • Critics with a bearish tilt often focus on this trailing loss profile, and the numbers here give them clear talking points, because the swing from a first half FY 2024 profit of US$0.4 million to a first half FY 2025 loss of US$0.9 million shows that profitability has not kept pace with the 51.1% revenue increase.
    • The fact that BGM Group is still unprofitable on a trailing basis reinforces the concern that higher sales have not yet translated into positive net income.
    • With basic EPS in the trailing period at roughly a US$0.18 loss while the current share price is US$0.30, bears will likely frame the stock as a pure loss making situation for now, with no positive trailing EPS to support it.

Mixed P/S valuation and recent dilution

  • BGM Group’s P/S ratio of 3x sits below the broader US Pharmaceuticals industry average of 6.7x but above its peer group at 1.5x, against a share price of US$0.30.
  • What creates tension for both bullish and bearish views is that this P/S level looks comparatively low versus the wider industry yet high against closer peers, and when combined with substantial shareholder dilution over the past year and a highly volatile share price over the last 3 months, holders have to weigh the 51.1% revenue rise against the effect of issuing more shares and recent price swings.
    • Bulls might argue that trading below the broader industry’s P/S gives some valuation cushion, especially if revenue remains at or above the current US$37.9 million trailing level.
    • Bears, in contrast, can point to the peer P/S of 1.5x, the company’s unprofitable status, and the past year’s dilution as reasons to question whether even a 3x sales multiple is generous without evidence of improved earnings.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on BGM Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given the mixed picture around BGM Group’s revenue, losses, and valuation, how do you see the balance of risk and reward here? Take a closer look at the underlying data, stress test your own expectations, and then weigh those findings against the 1 key reward and 3 important warning signs.

See What Else Is Out There

BGM Group is growing revenue but remains loss making, has reported a trailing 12 month net loss of US$19.9 million, and continues to show negative basic EPS.

If you are concerned about that ongoing loss profile and the recent swing from profit to loss, use the 81 resilient stocks with low risk scores to quickly focus on companies where earnings, volatility, and balance sheet strength may better match your risk tolerance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.